Practical aspects of the oral new anticoagulants

    Research output: Contribution to journalArticle

    30 Citations (Scopus)

    Abstract

    After years of only oral vitamin K antagonists, there are new many new antithrombotic agents in development and on entering the marketplace. This review will analyze clinical trial results for these new agents-especially dibigatran, rivaroxaban, and apixiban. Also to be discussed are practical aspects of use of these new agents such monitoring, reversal, and use before procedures.

    Original languageEnglish (US)
    Pages (from-to)586-590
    Number of pages5
    JournalAmerican Journal of Hematology
    Volume86
    Issue number7
    DOIs
    StatePublished - Jul 2011

    Fingerprint

    Fibrinolytic Agents
    Vitamin K
    Anticoagulants
    Clinical Trials
    Rivaroxaban

    ASJC Scopus subject areas

    • Hematology

    Cite this

    Practical aspects of the oral new anticoagulants. / Deloughery, Thomas.

    In: American Journal of Hematology, Vol. 86, No. 7, 07.2011, p. 586-590.

    Research output: Contribution to journalArticle

    @article{b17c036718d14f4fb2368f37b2350ad4,
    title = "Practical aspects of the oral new anticoagulants",
    abstract = "After years of only oral vitamin K antagonists, there are new many new antithrombotic agents in development and on entering the marketplace. This review will analyze clinical trial results for these new agents-especially dibigatran, rivaroxaban, and apixiban. Also to be discussed are practical aspects of use of these new agents such monitoring, reversal, and use before procedures.",
    author = "Thomas Deloughery",
    year = "2011",
    month = "7",
    doi = "10.1002/ajh.22021",
    language = "English (US)",
    volume = "86",
    pages = "586--590",
    journal = "American Journal of Hematology",
    issn = "0361-8609",
    publisher = "Wiley-Liss Inc.",
    number = "7",

    }

    TY - JOUR

    T1 - Practical aspects of the oral new anticoagulants

    AU - Deloughery, Thomas

    PY - 2011/7

    Y1 - 2011/7

    N2 - After years of only oral vitamin K antagonists, there are new many new antithrombotic agents in development and on entering the marketplace. This review will analyze clinical trial results for these new agents-especially dibigatran, rivaroxaban, and apixiban. Also to be discussed are practical aspects of use of these new agents such monitoring, reversal, and use before procedures.

    AB - After years of only oral vitamin K antagonists, there are new many new antithrombotic agents in development and on entering the marketplace. This review will analyze clinical trial results for these new agents-especially dibigatran, rivaroxaban, and apixiban. Also to be discussed are practical aspects of use of these new agents such monitoring, reversal, and use before procedures.

    UR - http://www.scopus.com/inward/record.url?scp=79959328410&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=79959328410&partnerID=8YFLogxK

    U2 - 10.1002/ajh.22021

    DO - 10.1002/ajh.22021

    M3 - Article

    C2 - 21674571

    AN - SCOPUS:79959328410

    VL - 86

    SP - 586

    EP - 590

    JO - American Journal of Hematology

    JF - American Journal of Hematology

    SN - 0361-8609

    IS - 7

    ER -